"For the millions of people who suffer from atopic dermatitis (AD), or eczema, ENS-002 represents a potential paradigm shift in care." Current treatments like steroids and immunosuppressants may come ...

There are lots of misconceptions around eczema, from poor hygiene to the skin condition disappearing on its own - there is a ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Eczema, or atopic dermatitis, is a condition that causes dry, itchy, and irritated skin. Treatment involves hydrating the skin, restoring the skin barrier, managing inflammation, and other goals.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

When it comes to medical marketing, some campaigns are built around celebrity spokespeople while others opt for first-person ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory ...